<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311804</url>
  </required_header>
  <id_info>
    <org_study_id>02-2010</org_study_id>
    <secondary_id>Ministry of Health</secondary_id>
    <nct_id>NCT01311804</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Periarticular Parecoxib Sodium for Pain Management in Total Knee Arthroplasty</brief_title>
  <official_title>An Open Label,Multicentre, Randomized Trial to Determine the Efficacy of Periarticular Parecoxib Sodium In A Multimodal Cocktail vs Intravenous Parecoxib Sodium for Pain Management in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Research Objective:&#xD;
&#xD;
      The primary objective of this study is to determine efficacy of periarticular parecoxib&#xD;
      sodium in a multimodal cocktail versus intravenous parecoxib injections for pain management&#xD;
      in total knee arthroplasty&#xD;
&#xD;
      Secondary Research Objective:&#xD;
&#xD;
        -  To determine if perioperative use of parecoxib sodium was associated with improved&#xD;
           clinical outcomes&#xD;
&#xD;
        -  To evaluate the safety, in terms of adverse events; serious adverse events and&#xD;
           tolerability of parecoxib sodium in periarticular injections in a multimodal cocktail&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open label, parallel randomized trial designed to evaluate the&#xD;
      efficacy and safety of periarticular parecoxib sodium compared to intravenous parecoxib&#xD;
      sodium.&#xD;
&#xD;
      125 patients with primary knee osteoarthritis from 4 participating sites who meet&#xD;
      inclusion/exclusion criteria will be enrolled into the trial. After initial screening,&#xD;
      patients will attend clinic for baseline examination. Subjects will then randomly allocated&#xD;
      to periarticular parecoxib sodium or intravenous sodium in ratio of 1:1. patients are&#xD;
      observed at post-operative 6, 12, 24 hours, subsequently daily for 4 days and finally at 2&#xD;
      week follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative pain control</measure>
    <time_frame>4 days</time_frame>
    <description>Post operative pain control( Visual Analogue Scale) with 0 corresponding to &quot;no pain&quot; and 10 to&quot; the worst imaginable pain&quot;. Pain will be measured 1st 6 hours, 12 hours, 24 hours and daily for 4 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and duration of adverse events</measure>
    <time_frame>4 days</time_frame>
    <description>Morphine consumption&#xD;
Metochlopromide usage during the 4 days&#xD;
Lactulose usage during the 4 days&#xD;
Range of motion measured by physiotherapist at 24 hours and daily for 4 days&#xD;
time to single leg raise&#xD;
time to ambulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Unilateral Primary Osteoarthritis of Knee</condition>
  <arm_group>
    <arm_group_label>periarticular parecoxib sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be given periarticular parecoxib sodium injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous parecoxib sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous parecoxib sodium will be given during total knee arthroplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parecoxib sodium</intervention_name>
    <description>periarticular parecoxib sodium injection will be given during total knee arthroplasty</description>
    <arm_group_label>periarticular parecoxib sodium</arm_group_label>
    <other_name>dynastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parecoxib sodium</intervention_name>
    <description>intravenous parecoxib sodium during total knee arthroplasty</description>
    <arm_group_label>intravenous parecoxib sodium</arm_group_label>
    <other_name>dynastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary knee osteoarthritis on treatment and planned for unilateral&#xD;
             total knee arthroplasty and on spinal/general anesthesia&#xD;
&#xD;
          -  Subjects age more than 50 and less than 85 years&#xD;
&#xD;
          -  Patients with body weight at least 50 kg and not more than 50%above ideal body weight&#xD;
&#xD;
          -  Written informed consent obtained from patient or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are attempting to conceive/pregnant&#xD;
&#xD;
          -  Known allergy or hypersensitivity to cocktail regime or to COX-2 inhibitors&#xD;
&#xD;
          -  History of bleeding disorders or coagulation defect&#xD;
&#xD;
          -  Patients with abnormal liver profile&#xD;
&#xD;
          -  Patients with history of stroke or major neurological defect&#xD;
&#xD;
          -  Patients with neuropathic pain/sensory disorder&#xD;
&#xD;
          -  Patients with peptic ulceration or anticoagulant use within 1 month&#xD;
&#xD;
          -  History of previous major knee surgery/trauma&#xD;
&#xD;
          -  Patients with renal insufficiency&#xD;
&#xD;
          -  History of revision total knee arthroplasty&#xD;
&#xD;
          -  Patients with knee deformity &gt; 20 degrees&#xD;
&#xD;
          -  Patients planned for bilateral knee arthroplasty during the same setting&#xD;
&#xD;
          -  Patients with significant bone loss requiring augmentation&#xD;
&#xD;
          -  Patients with history of using NSAIDs 24 hours before the surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeap Ewe Juan</last_name>
    <role>Principal Investigator</role>
    <affiliation>MOH Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanthini Govindasamy</last_name>
    <phone>+603-26924249</phone>
    <email>shanthini@crc.gov.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Tuanku Fauziah</name>
      <address>
        <city>Kangar</city>
        <state>Perlis</state>
        <zip>01000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Yeap Ewe Juan</last_name>
      <phone>+604-976 3333</phone>
    </contact>
    <investigator>
      <last_name>Yeap Ewe Juan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Yeap Ewe Juan</name_title>
    <organization>Name/Official Title: Dr. Yeap Ewe Juan</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

